About Jeremy Abramson, MD

Dr. Abramson is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Associate Professor of Medicine at Harvard Medical School.  Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Masters Degree in Medical Sciences from Harvard Medical School.  He completed a residency in Internal Medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. Dr. Abramson is board certified in Medical Oncology.

Dr. Abramson's clinical and research interests are in lymphoid malignancies, including all non-Hodgkin lymphomas, as well as Hodgkin lymphoma, and chronic lymphoid leukemias.  His research involves identifying new targets for therapy in lymphomas and lymphoid leukemias, and the design and conduct of clinical trials of new cancer therapies and cellular immunotherapies in these diseases. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and a Fellow of the American College of Physicians.  Dr. Abramson is the author of numerous papers and book chapters on lymphoma, and lectures widely.

Clinical Interests:



Mass General Cancer Center: Hematology Oncology
55 Fruit St.
Boston, MA 02114
Phone: 617-724-4000
Fax: 617-726-8330

Medical Education

  • MD, Mount Sinai School of Medicine
  • Residency, Massachusetts General Hospital
  • Fellowship, Brigham and Women's Hospital
  • Fellowship, Dana Farber Cancer Institute
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Abramson designs and conducts clinical trials of novel therapies and cellular immunotherapies including CAR T-cells for the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma (Hodgkin's disease), and chronic lymphocytic leukemia (CLL). 


  • Select Publications:

    • Abramson JS and Shipp MA. Advances in the biology, natural history and therapy of diffuse large B-cell lymphoma. Blood 2005.
    • Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis and management. Oncologist 2006.
    • Abramson JS, Chatterji M et al. A 51-year-old woman with splenomegaly and anemia. N Engl J Med 2008.
    • Abramson JS, Chen W, et al. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haem 2009.
    • Abramson JS. Approach to the Patient with Lymphoma. In: Goroll AH and Mulley AG, editors. Primary Care Medicine 6th ed. LW&W 2009.
    • Abramson JS, Digumarthy S et al. A 56-Year-Old Woman with Fever, Rash, and Lymphadenopathy. N Engl J Med 2009.
    • Abramson JS and Scadden DT. Neoplasms in Acquired Immunodeficiency Syndrome. In: Kufe DW, et al. editors. Cancer Medicine 8. BC Decker 2010.
    • Canellos GP, Abramson JS et al. Treatment of favorable, limited-stage Hodgkins lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010.
    • Abramson JS, Hellmann M et al. Intravenous Methotrexate as CNS prophylaxis is associated with a low risk of CNS recurrence in high risk patients with Diffuse Large B Cell Lymphoma. Cancer 2010.
    • Barnes JA. and Abramson JS. Evaluation of the addition of Rituximab to CODOX-M/IVAC for Burkitt's Lymphoma. Ann Oncol 2011.

Reviews: Comments and Ratings